ProQR Therapeutics N.V. reported a net loss of €22.3 million, or €0.21 per diluted share, for the six-month period ended June 30, 2025, compared to a net loss of €10.4 million, or €0.13 per diluted share, for the same period in 2024. Research and development costs increased to €23.7 million for the first half of 2025, up from €16.3 million in the prior-year period.
As of June 30, 2025, ProQR held approximately €119.8 million in cash and cash equivalents, a decrease from €149.4 million at December 31, 2024. Net cash used in operating activities for the first half of 2025 was €27.2 million, compared to €21.4 million used in the same period last year.
During the first half of 2025, the company achieved $2.0 million, or approximately €1.8 million, in milestone payments from its collaboration agreement with Eli Lilly. ProQR confirmed the submission of the Clinical Trial Application for AX-0810 and expects to share initial data from the trial in the fourth quarter of 2025, while also progressing AX-2402 for Rett syndrome.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.